| Outcome Measures: |
Primary: 24 Hour Weighted Mean Glucose (WMG) At 2 Weeks, The 24 hour WMG was measured after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment. Glucose was measured over a 24 hour period by having participants wear two continuous glucose monitors (CGM), which produced an average glucose value approximately every 5 minutes. Using these values, the concentration of glucose was calculated from Area Under the Curve 0-24 hours (AUC 0-24hr), and was expressed as 24 hour WMG., At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment | Secondary: Hemoglobin A1C (HbA1C) At 2 Weeks, Blood samples were taken after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%)., At 2 weeks after Placebo treatment and again at 2 weeks after Vildagliptin treatment|HbA1C At 12 Weeks, Blood samples were taken after 2 weeks of placebo treatment, and again after 12 weeks of vildagliptin treatment to measure the percentage of glycated hemoglobin, HbA1C. Units are therefore presented as HbA1c (%)., At 2 weeks after Placebo treatment and again at 12 weeks after Vildagliptin treatment
|
